Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

@article{Shepherd2000ProspectiveRT,
  title={Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.},
  author={Frances A. Shepherd and Janet E. Dancey and Rodryg Ramlau and Karin V Mattson and Richard J Gralla and Mark A. O'Rourke and Nathan Levitan and Laurent Gressot and Mark David Vincent and Ronald Burkes and Susan Coughlin and Y Kim and Jocelyne B{\'e}rille},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2000},
  volume={18 10},
  pages={
          2095-103
        }
}
  • F. Shepherd, J. Dancey, J. Bérille
  • Published 10 May 2000
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE To evaluate whether treatment with single-agent docetaxel would result in longer survival than would best supportive care in patients with non-small-cell lung cancer who had previously been treated with platinum-based chemotherapy. Secondary end points included assessment of response (docetaxel arm only), toxicity, and quality of life. PATIENTS AND METHODS Patients with performance statuses of 0 to 2 and stage IIIB/IV non-small-cell lung cancer with either measurable or evaluable… 

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

  • N. HannaF. Shepherd P. Bunn
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
Treatment with pemetrexed resulted in clinically equivalent efficacy outcomes, but with significantly fewer side effects compared with docetaxel in the second-line treatment of patients with advanced NSCLC and should be considered a standard treatment option for second-liners when available.

Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

TLDR
The higher non-haematological toxicity of docetaxel, particularly pulmonary toxicity and diarrhoea, is of concern and warrants further investigation.

Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.

TLDR
It is concluded that salvage gemcitabine in this dose and schedule is safe and tolerable in previously platinum-treated patients with NSCLC.

Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer

TLDR
This study demonstrated that this non-platinum doublet (docetaxel+gemcitabine) given on a weekly schedule for advanced NSCLC was well tolerated with efficacy comparable to that reported with platinum-based chemotherapy regimens.

Phase II study of docetaxel-plus-bevacizumab combination therapy in patients previously treated for advanced non-squamous non-small cell lung cancer.

TLDR
The combination regimen of docetaxel-plus-bevacizumab is very active in patients with previously-treated Nsq NSCLC and warrants further research.

Phase II study of docetaxel/vinorelbine in patients with non-small-cell-lung cancer previously treated with platinum-based chemotherapy.

TLDR
It is confirmed that the docetaxel/vinorelbine schedule has activity in NSCLC patients pretreated with platinum-based therapies.
...

References

SHOWING 1-10 OF 20 REFERENCES

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

TLDR
Patients who received docetaxel had a longer time to progression and a greater progression-free survival at 26 weeks and the 1-year survival was significantly greater with D75 than with the control treat...

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.

  • F. FossellaJ. Lee B. Glisson
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1995
TLDR
Docetaxel administered at 100 mg/m2 intravenously every 3 weeks has notable activity against platinum-refractory non-small-cell lung cancer, with a 21% major response rate.

Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study.

TLDR
Docetaxel is highly active in metastatic breast cancer, even as a third-line treatment, and can be considered as an efficient standard option in second- line treatment.

Management strategies for recurrent non-small cell lung cancer.

Because the benefit of first-line chemotherapy for non-small cell lung cancer (NSCLC) may be marginal, the use of chemotherapy in the second-line setting for the patient who has failed primary

Docetaxel: meeting the challenge of non-small cell lung cancer management.

TLDR
Response rates of docetaxel were comparable to or better than those seen with previous single-agent chemotherapeutic regimens for advanced NSCLC and even with some combination treatments, with a tolerable adverse event profile.

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

TLDR
The results of this meta-analysis suggest that chemotherapy may have a role in treating non-small cell lung cancer, and reached conventional levels of significance when used with radical radiotherapy and with supportive care.

Chemotherapy for non-small cell lung cancer: have we reached a new plateau?

The last decade has seen the introduction of several new chemotherapeutic agents that have activity against non-small cell lung cancer (NSCLC) and produce single-agent response rates of > or = 20% in

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.

TLDR
MTA seems to have clinically meaningful activity as a single agent against advanced NSCLC, and nonhematologic toxicity was generally mild or moderate, but 39% of patients developed a grade 3 skin rash.

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer.

TLDR
MVP is a pragmatic inexpensive chemotherapy regimen that offers useful symptom palliation in patients with advanced NSCLC and merits a 1-2 course therapeutic trial in such patients.